L-阿卓糖 | 1949-88-8

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: L-阿卓糖
• 中文别名: L(-)-阿卓糖
• 英文名称: L-altrose
• 英文别名: alpha-L-altrose；(2R,3S,4S,5S)-2,3,4,5,6-pentahydroxyhexanal
• CAS: 1949-88-8
• 化学式: C₆H₁₂O₆
• 分子量: 180.158
• InChiKey: GZCGUPFRVQAUEE-AZGQCCRYSA-N

物化性质

• 熔点：
  107-109℃
• 沸点：
  232.96°C (rough estimate)
• 密度：
  1.581
• 溶解度：
  DMSO（轻微、超声处理）、甲醇（轻微、加热）、水（轻微）
• 稳定性/保质期：
  常温常压下稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  118
• 氢给体数：
  5
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2912491000
• 储存条件：
  密封保存，应储存在阴凉干燥的库房中。

SDS

Name:	L(-)-Altrose 99% Material Safety Data Sheet
Synonym:	L-Altropyranose
CAS:	1949-88-8

Section 1 - Chemical Product MSDS Name:L(-)-Altrose 99% Material Safety Data Sheet
Synonym:L-Altropyranose

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1949-88-8	L(-)-Altrose	99%	217-764-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1949-88-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H12O6
Molecular Weight: 180.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1949-88-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
L(-)-Altrose - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1949-88-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1949-88-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1949-88-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

L-Altrose是一种生物化学试剂，可用于生物材料或有机化合物，在生命科学相关研究中发挥重要作用。

反应信息

• 作为反应物：
  描述：

  L-阿卓糖 在 nickel kieselguhr 、 水 作用下， 100.0 ℃ 、13.04 MPa 条件下， 生成 L-talitol
  参考文献：
  名称：

  L-Talitol

  摘要：

  DOI：

  10.1021/ja01223a505
• 作为产物：
  描述：

  在 palladium dihydroxide 氢气 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 L-阿卓糖
  参考文献：
  名称：

  从常见的手性结构单元到醛糖己糖的新的聚合路线。

  摘要：

  [文本中的反应]从常见的环己酸手性结构单元开始，开发了一种非对映控制的途径来合成8个醛己糖。

  DOI：

  10.1021/ol015733i

文献信息

• Two-Step Synthesis of Per-<i>O</i>-acetylfuranoses: Optimization and Rationalization
  作者：Rémy Dureau、Laurent Legentil、Richard Daniellou、Vincent Ferrières

  DOI：10.1021/jo201913f

  日期：2012.2.3

  A simple two-step procedure yielding peracetylated furanoses directly from free aldoses was implemented. Key steps of the method are (i) highly selective formation of per-O-(tert-butyldimethylsilyl)furanoses and (ii) their clean conversion into acetyl ones without isomerization. This approach was easily applied to galactose and structurally related carbohydrates such as arabinose, fucose, methyl galacturonate

  实现了一个简单的两步程序，直接从游离醛糖中产生过乙酰化呋喃糖酶。该方法的关键步骤是（i）高选择性形成过-O-（叔丁基二甲基甲硅烷基）呋喃糖和（ii）在不异构化的情况下将其干净地转化为乙酰基。这种方法很容易应用于半乳糖和与结构相关的碳水化合物，例如阿拉伯糖，岩藻糖，半乳糖醛酸甲酯和N-乙酰半乳糖胺得到相应的过乙酰化目标。该方法的成功取决于至少三个参数的控制：（i）起始未保护糖的互变异构平衡，（ii）靶向呋喃糖酶和甲硅烷基化剂的空间位阻，最后，（iii）保护基相互转化期间的每个软亲核试剂。
• Synthesis of Hexp-(1 → 4)-β-d-GlcpNac-(1 → 2)-α-d-Manp-(1 → O)(CH2)7CH3 probes for exploration of the substrate specificity of glycosyltransferases: Part II, Hex = 3-O-methyl-β-d-Gal, 3-deoxy-β-d-Gal, 3-deoxy-3-fluoro-β-d-Gal, 3-amino-3-deoxy-β-d-Gal, β-d-Gul, α-l-Alt, or β-l-Gal11Dedicated to Professor Dr. Hans Paulsen on the occasion of his 75th birthday.
  作者：Johannes A.L.M van Dorst、Cornelis J van Heusden、Jaana M Tikkanen、Johannis P Kamerling、Johannes F.G Vliegenthart

  DOI：10.1016/s0008-6215(96)00266-2

  日期：1997.1

  -Man p -(1 → O)(CH 2 ) 7 CH 3 , 3-deoxy-3-fluoro-β- d -Gal p -(1 → 4)-β- d -Glc p NAc-(1 → 2)-α- d -Man p -(1 → O)(CH 2 ) 7 CH 3 , 3-amino-3-deoxy-β- d -Gal p -(1 → 4)-β- d -Glc p NAc-(1 → 2)-α- d -Man p -(1 → O)(CH 2 ) 7 CH 3 , β- d -Gul p -(1 → 4)-β- d -Glc p NAc-(1 → 2)-α- d -Man p -(1 → O)(CH 2 ) 7 CH 3 , β- l -Gal p -(1 → 4)-β- d -Glc p NAc-(1 → 2)-α- d -Man p -(1 → O)(CH 2 ) 7 CH 3 , and α- l -Alt

  摘要三糖β-d -Gal p-（1→4）-β-d -Glc p NAc-（1→2）-α-d -Man p-（1→O）（CH 2）7的七个类似物已经合成了CH 3作为参与N-乙酰基乳糖胺型N-聚糖的链终止的糖基转移酶的潜在底物。这些化合物包括：3-O-甲基-β-d -Gal p-（1→4）-β-d -Glc p NAc-（1→2）-α-d -Man p-（1→O）（ CH 2）7 CH 3，3-脱氧-β-d-Gal p-（1→4）-β-d-Glc p NAc-（1→2）-α-d -Man p-（1→O） （CH 2）7 CH 3，3-脱氧-3-氟-β-d-Gal p-（1→4）-β-d-Glc p NAc-（1→2）-α-d-Man p- （1→O）（CH 2）7 CH 3，3-氨基-3-脱氧-β-d-Gal p-（1→4）-β-d -Glc p NAc-（1→2）-α- d -Man p-（1→O）（CH
• Design, Synthesis, DFT, Molecular Docking, and Biological Evalution of Pyrazole Derivatives as Potent Acetyl Cholinestrease Inhibitors
  作者：Huda E. Abdelwahab、Hesham Z. Ibrahim、Alaa Z. Omar

  DOI：10.1016/j.molstruc.2022.134137

  日期：2023.1

  synthesised from the reaction of formyl furan derivatives with acetophenone to give chalcone, followed by reaction with hydrazinehydrate and condensation with different aldehydes. The purified pyrazole derivatives were in-vitro screened for their acetyl cholinesterase (AChE) inhibitory activities using Ellman's method. The pyrazole derivative containing benzylidene moiety inhibited the AChE enzyme with an IC50

  阿尔茨海默病 (AD) 是一种与年龄相关的慢性和进行性神经退行性疾病，影响认知、记忆和行为。阿尔茨海默病 (AD) 症状的治疗已通过几种可行的治疗方式进行；其中之一是增强神经系统中的神经传递，例如乙酰胆碱。乙酰胆碱被乙酰胆碱酯酶 (AChE) 水解成乙酸盐和胆碱。为了延缓乙酰胆碱的水解，采取其传递规律；AChE 抑制剂通过与酶而不是乙酰胆碱相互作用来防止乙酰胆碱的快速水解。有鉴于此，合成了一系列新的吡唑分子，并将其作为潜在的 AchE 抑制剂进行了检测。目标吡唑类化合物由甲酰基呋喃衍生物与苯乙酮反应生成查尔酮，再与水合肼反应，再与不同的醛类缩合合成。使用 Ellman 方法对纯化的吡唑衍生物的乙酰胆碱酯酶 (AChE) 抑制活性进行体外筛选。含有亚苄基的吡唑衍生物通过 IC 抑制 AChE 酶50值为 5.28 M。进行分子对接研究以测试它们对 AchE 的活性。进行密度泛函理论 (DFT)
• Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
  申请人：ENGENE, INC.

  公开号：US10456481B2

  公开（公告）日：2019-10-29

  Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

  本文提供了壳聚糖衍生物纳米粒子，包括用阳离子氨基酸和亲水多元醇官能化的壳聚糖；以及制造和使用这种纳米粒子的方法，例如用于体内基因递送。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。